Upgrade to SI Premium - Free Trial

Baird Reiterates Outperform Rating on Biohaven Pharma (BHVN), "no change to outlook"

September 10, 2026 10:14 AM
Baird analyst Brian Skorney reiterated an Outperform rating and $42.00 price target on Biohaven Pharma (NYSE: BHVN).The analyst commented: "No ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments